$EVAX News
Last published 2d ago
- 2d agoEVAXEvaxion files amendment to registration statement related to 2025 EIB debt settlement agreementGlobeNewswireCOPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an
- 2d agoEVAXEvaxion files amendment to registration statement related to 2025 EIB debt settlement agreementGlobeNewswireCOPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an amendment to its registration statement on Form F-1 related to the 2025 debt settlement agreement with The European Investment Bank (EIB) with the US Securities and Exchange Commission.
- 5d agoEVAXNew phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01GlobeNewswireDetection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responsesData further underlines the strong predictive performance of Evaxion’s AI-Immunology™ platformThe new biomarker
- 5d agoEVAXNew phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01GlobeNewswireDetection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responsesData further underlines the strong predictive...
- 1w agoEVAXEvaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 MeetingGlobeNewswireThe data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemiaData will be presented in a poster session at the American Society of Hematology (ASH) Annual Meeting
- 1w agoEVAXEvaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual MeetingGlobeNewswireNew data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company
- 1w agoEVAXEvaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solutionGlobeNewswireThis international award, honoring "the best of the best" in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S
- 2w agoEVAXEvaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01GlobeNewswireEVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients with advanced
- 3w agoEVAXEvaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01GlobeNewswireThree-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 CongressData supplements unprecedented two-year data from the trial including a 75% Objective Response
- 1mo agoEVAXEvaxion applies its AI-Immunology™ platform in autoimmune diseasesGlobeNewswireAutoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologiesThe unique capabilities of
- 2mo agoEVAXEvaxion - Business update and second quarter 2026 financial results - EVAXION AEarnings Call TranscriptsI'm Helen Tatum-Martin, I'm the Chief Executive of Evaction, and we're delighted today to be presenting our Q2 business update. I'm joined today on the call by Vigida Rona, our CSO and COO, who will provide an overview o
- 2mo agoEVAXEvaxion announces business update and second quarter 2026 financial resultsGlobeNewswireCOPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and
- 2mo agoEVAXEvaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine programGlobeNewswireEVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platformGlioblastoma is
- 2mo agoEVAXEvaxion to announce business update and second quarter 2026 financial results on August 20, 2026GlobeNewswireCOPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business
- 3mo agoEVAXEvaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026GlobeNewswireThree-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into the vaccine’s effect
- 4mo agoEVAXEvaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1GlobeNewswireThe new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1EVX-V1 is a next-generation, multi-component vaccine program
- 4mo agoEVAXEvaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus WorkshopGlobeNewswireNew preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidatePoster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal,
- 5mo agoEVAXEvaxion receives Prix Galien UK Award for Best digital health solutionGlobeNewswireCOPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix
- 5mo agoEVAXEvaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemiaGlobeNewswireEVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and induce targeted
- 6mo agoEVAXEvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 CongressGlobeNewswireData will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing
- 6mo agoEVAXEvaxion announces business update and first quarter 2026 financial resultsGlobeNewswireCOPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and
- 6mo agoEVAXEvaxion to announce business update and first quarter 2026 financial results on May 7, 2026GlobeNewswireCOPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and
- 6mo agoEVAXEvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating OfficerGlobeNewswireManagement remit expansion reflecting organization alignment to maximize external engagement and strategy execution COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio
- 6mo agoEVAXEvaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trialGlobeNewswireNew phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune responseThe results reinforce that Evaxion's pioneering AI platform,
- 6mo agoEVAXNew data demonstrates the unique scalability of Evaxion's AI-Immunology™ platform in glioblastomaGlobeNewswireData analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a
- 6mo agoEVAXEvaxion concludes Annual General MeetingGlobeNewswireCOPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting
- 7mo agoEVAXEvaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01GlobeNewswireTrial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data including a 75% Objective
- 7mo agoEVAXEvaxion to present novel AI-based polio vaccine design concepts at the World Vaccine CongressGlobeNewswireUsing its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently usedThe
- 8mo agoEVAXEvaxion announces business update and full year 2025 financial resultsGlobeNewswireCOPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and
- 8mo agoEVAXEvaxion plans to file 2025 annual report later todayGlobeNewswireCOPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing
- 8mo agoEVAXEvaxion to announce business update and full year 2025 financial results on March 5, 2026GlobeNewswireCOPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update
- 10mo agoEVAXEvaxion expands AI-Immunology™ platform into autoimmune diseasesGlobeNewswireEvaxion adds autoimmune disease as a third disease area as it expands its therapeutic focusIn future, Evaxion's proprietary AI-Immunology™ platform will enable the discovery and development of drug candidates
- 10mo agoEVAXEvaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2GlobeNewswireMSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in
- 11mo agoEVAXEvaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual MeetingGlobeNewswireDesigned with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune responses
- 11mo agoEVAXEvaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1GlobeNewswireEvaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these
- 12mo agoEVAXEvaxion announce 2026 financial calendarGlobeNewswireCOPENHAGEN, Denmark, November 12, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its financial calendar for
- 1y agoEVAXEvaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01GlobeNewswireNew biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the
- 1y agoEVAXEvaxion announces business update and third quarter 2025 financial resultsGlobeNewswireCOPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces
- 1y agoEVAXEvaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidateGlobeNewswireEvaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platformEVX-04 is a therapeutic cancer vaccine candidate designed for
- 1y agoEVAXCorrection: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025GlobeNewswireCorrecting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a
- 1y agoEVAXEvaxion to announce business update and third quarter 2025 financial results on November 6, 2025GlobeNewswireCOPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report
- 1y agoEVAXEvaxion raises $7.2 million, extending cash runway to second half of 2027GlobeNewswireGross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross inflow of cash of $14.7 million since the end of the second quarter 2025Evaxion now has
- 1y agoEVAXEvaxion appoints Dr Helen Tayton-Martin as new Chief Executive OfficerGlobeNewswireDr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of
- 1y agoGTBPEVAXRNXTEDAP+1Natural Killer Cell Therapies Lead $254B Immunotherapy Market TransformationPR NewswireEquity InsiderNews Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more...
- 1y agoEVAXEvaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01GlobeNewswire75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed in all patients
- 1y agoEVAXEvaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025GlobeNewswirePresentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into
- 1y agoEVAXEvaxion expands AI-Immunology™ platform with automated vaccine design moduleGlobeNewswireNew platform module automates previous manual vaccine design processes, improving quality and dramatically reducing time and resource requirementsAI-Immunology™, already superior in vaccine target discovery, now
- 1y agoEVAXEvaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual MeetingGlobeNewswireNew biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions to EVX-01's
- 1y agoEVAXEvaxion out-licenses vaccine candidate EVX-B3 to MSDGlobeNewswireMSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 with Evaxion eligible
- 1y agoEVAXEvaxion to present at several conferences during the second half of 2025GlobeNewswireEvaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a